Cittadine Andrew reported option exercise involving 4,384 shares of Monopar Therapeutics on Sep 30, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Operating Officer
Chief Operating Officer
Filed Oct 2, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
—Shares × reported price
Shares traded
4,384Common Stock
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
59,998Direct
Trade date
Sep 30, 2026Option exercise
Filed
Oct 2, 2026, 6:15 PM ET2-day reporting delay
Accession
0001437749-26-031927Code M · Transaction 235744
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 30, 2026Tax withholding1,944$79.67−$154,878.48Trade 235745
Sep 30, 2026Option exercise4,384$0.00$0Trade 235746
3 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

MNPR price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
MNPR · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +44%1w ago +15%1d ago +2.6%
Returns since7d +1.3%30d −9.8%90d180d1y

Footnotes in full

F1: Represents shares acquired on vesting and settlement of restricted stock units. F2: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units. F3: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4: On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F5: On December 2, 2025, the reporting person was granted 13,919 restricted stock units, vesting 6/48ths (1,740) on June 30, 2026, and 3/48ths (870 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.